Evidence map›Paper›PMID 35160308›Full record

ReviewJournal of clinical medicine2022

Do the Current Guidelines for Heart Failure Diagnosis and Treatment Fit with Clinical Complexity?

Paolo Severino, Andrea D'Amato, Silvia Prosperi, Alessandra Dei Cas, Anna Vittoria Mattioli, Antonio Cevese, Giuseppina Novo, Maria Prat, Roberto Pedrinelli, Riccardo Raddino and 7 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 37 citations in OpenAlex.

  1. Non-Oncology Biomarkers in Precision Medicine: A Narrative Review.Therapeutic innovation & regulatory science · 2026
    Review
  2. Non-Oncology Biomarkers in Precision Medicine: A Narrative Review.Therapeutic innovation & regulatory science · 2026
    Review
  3. HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity.Journal of cardiovascular development and disease · 2026
    Article
  4. Review
  5. Review
  6. Observational
  7. Article
  8. Review
  9. Observational
  10. Review
  11. Strategy for an early simultaneous introduction of four-pillars of heart failure therapy: results from a single center experience.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024
    Observational
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Paolo SeverinoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.ORCID 0000-0001-6211-4482
Andrea D'AmatoDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.
Silvia ProsperiDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.
Alessandra Dei CasDepartment of Medicine and Surgery, University of Parma, 43125 Parma, Italy.ORCID 0000-0002-8666-4849
Anna Vittoria MattioliSurgical, Medical and Dental Department of Morphological Sciences Related to Transplant, Oncology and Regenerative Medicine, University of Modena and Reggio Emilia, 41121 Modena, Italy.ORCID 0000-0003-1487-9530
Antonio CeveseDepartment of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Via Casorati 43, 37131 Verona, Italy.
Giuseppina NovoDivision of Cardiology, University Hospital "P. Giaccone", University of Palermo, 90133 Palermo, Italy.
Maria PratDepartment of Health Sciences, University of Piemonte Orientale "A. Avogadro", 28100 Novara, Italy.
Roberto PedrinelliDepartment of Clinical and Experimental Medicine, University of Pisa, Via Roma, 67, 56126 Pisa, Italy.ORCID 0000-0001-7745-3890
Riccardo RaddinoSection of Cardiovascular Diseases, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, 25123 Brescia, Italy.
Sabina GallinaDepartment of Neuroscience, Imaging and Clinical Sciences, Institute of Advanced Biomedical Technologies, "G.D' Annunzio" University, 66100 Chieti, Italy.
Federico SchenaDepartment of Neuroscience, Biomedicine, and Movement Sciences, University of Verona, Via Casorati 43, 37131 Verona, Italy.
Corrado PoggesiDepartment of Clinical and Experimental Medicine, Division of Physiology, University of Florence, 50121 Florence, Italy.ORCID 0000-0003-2624-4778
Pasquale PagliaroDepartment of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.ORCID 0000-0002-4386-1383
Massimo ManconeDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.
Francesco FedeleDepartment of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, Viale del Policlinico, 155, 00161 Rome, Italy.
On Behalf Of The Italian National Institute For Cardiovascular Research Inrc
Policlinico Umberto I · ITUniversity of Verona · ITUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Brescia · ITUniversity of Chieti-Pescara · ITUniversity of Florence · ITUniversity of Modena and Reggio Emilia · ITUniversity of Palermo · ITUniversity of Parma · ITUniversity of Pisa · ITUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heart failure (HF) is a clinical syndrome defined by specific symptoms and signs due to structural and/or functional heart abnormalities, which lead to inadequate cardiac output and/or increased intraventricular filling pressure. Importantly, HF becomes progressively a multisystemic disease. However, in August 2021, the European Society of Cardiology published the new Guidelines for the diagnosis and treatment of acute and chronic HF, according to which the left ventricular ejection fraction (LVEF) continues to represent the pivotal parameter for HF patients' evaluation, risk stratification and therapeutic management despite its limitations are well known. Indeed, HF has a complex pathophysiology because it first involves the heart, progressively becoming a multisystemic disease, leading to multiorgan failure and death. In these terms, HF is comparable to cancer. As for cancer, surviving, morbidity and hospitalisation are related not only to the primary neoplastic mass but mainly to the metastatic involvement. In HF, multiorgan involvement has a great impact on prognosis, and multiorgan protective therapies are equally important as conventional cardioprotective therapies. In the light of these considerations, a revision of the HF concept is needed, starting from its definition up to its therapy, to overcome the old and simplistic HF perspective.

Indexed as

acute heart failurechronic heart failureheart failureleft ventricular ejection fractionNew York Heart Association classificationpathophysiologyphenotypestherapy

Identifiers

PMID35160308
PMCPMC8836547
OpenAlexW4210249186

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.